Skip to main content
. 2018 Dec 20;11:63–79. doi: 10.2147/CMAR.S186150

Figure 1.

Figure 1

Graphs show cumulative DFS and recurrence rates in patients with HCC after PATACE.

Notes: (A) Patients with higher APRI had better 3-year DFS benefits than those with low APRI score (P=0.013); (B) patients with higher APRI had better 5-year DFS benefits than those with low APRI score (P<0.01); (C) patients with higher APRI had lower OS than those with low APRI score (P=0.0035).

Abbreviations: APRI, aspartate aminotransferase-to-platelet ratio index; DFS, disease-free survival; HCC, hepatocellular carcinoma; OS, overall survival; PATACE, postoperative adjuvant transarterial chemoembolization.